Conferences and Publications

HBI-8000, HUYABIO Lead Clinical Program, is a Selective Histone Deacetylase Inhibitor with Therapeutic Benefits in Leukemia and in Solid Tumors

Farbod Shojaei, Bob Goodenow, Gloria Lee, Fairooz Kabbinavar & Mireille Gillings. Frontiers in Oncology, Cancer Molecular Targets and Therapeutics (2022)

View Publication Here

The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors

Bissonnette et al. BMC Cancer (2021) 21:969

View Publication Here

Society for Immunotherapy of Cancer (SITC)

November 9-14, 2020

Significant anti-tumor activity of HBI-8000, a class I histone deacetylase inhibitor (HDACi) in combination with nivolumab (NIVO) in anti-PD1 therapy-naïve advanced melanoma (TN-Mel)

View Poster Here

American Heart Association (AHA) Scientific Sessions

November 16-18, 2019

HBI-3000: A Novel Drug for Conversion of Atrial Fibrillation
– Phase 1 Study Results

View Poster Here

Society for Immunotherapy of Cancer (SITC)

November 7-11, 2018

A Phase 1b/2 Study of the Safety and Efficacy of HBI-8000-Nivolumab Combination in
Melanoma (MEL), Renal Cell Carcinoma (RCC) and Non-Small Cell Lung Cancer (NSCLC)

View Poster Here

T Cell Lymphoma Forum (TCLF)

Jan 28-30, 2016

Induction of cell death by HBI-8000, an HDAC inhibitor, in adult T-cell leukemia/lymphoma (ATL) is associated with activation of Bim and NLRP

View Poster Here

International Cancer Immunotherapy (ICI)

August 21–26, 2016

The HDAC inhibitor HBI-8000 enhances immunotherapy with either PD-1 or PD-L1 blockade in the MC38 and 4T1 models of colon cancer

View Poster Here

American Society of Hematology (ASH)

December 3-6, 2016

Oral HDAC Inhibitor HBI-8000 in Japanese Patients with Non–Hodgkin Lymphoma (NHL): Phase I Safety and Efficacy Results

View Poster Here